Physician profile
Jane E Drenkhahn
NPI 1316944382
$922.22
in general payments reported to CMS, 2019-2025
16 companies · $115 in 2025
The $115 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $354 · 2021: $99.87 · 2022: $153 · 2023: $83.01 · 2024: $117 · 2025: $115.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $298 · Education: $16.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $297.72 |
| Education | $16.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $128.04 | 2019-2021 | |
| Aurinia Pharma U.S., INC. | $126.00 | 2022 | |
| Baxter Healthcare | $115.00 | 2019 | |
| Nxstage Medical, INC. | $114.58 | 2025 | Pureflow Sl, Nxstage System One |
| Outset Medical INC | $100.13 | 2024 | |
| Mallinckrodt Hospital Products INC. | $83.01 | 2023 | Terlivaz |
| Mallinckrodt Enterprises LLC | $48.60 | 2019 | |
| Opko Pharmaceuticals, LLC | $46.97 | 2019 | |
| Novo Nordisk INC | $27.42 | 2022 | |
| Amgen INC. | $25.86 | 2019 | |
| Daiichi Sankyo INC. | $21.42 | 2019 | |
| Vifor Pharma, INC. | $20.42 | 2019 | |
| Covidien Lp | $19.27 | 2019 | |
| Travere Therapeutics, INC. | $16.89 | 2024 | |
| Fresenius USA Marketing, INC. | $16.84 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $11.77 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jane Drenkhahn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.